Revolution Medicines (NASDAQ: RVMD) recently received a number of ratings updates from brokerages and research firms:
- 8/12/2024 – Revolution Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $56.00 price target on the stock.
- 8/8/2024 – Revolution Medicines had its price target lowered by analysts at JPMorgan Chase & Co. from $55.00 to $54.00. They now have an “overweight” rating on the stock.
- 8/8/2024 – Revolution Medicines had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $59.00 price target on the stock.
- 8/8/2024 – Revolution Medicines had its price target lowered by analysts at Needham & Company LLC from $62.00 to $61.00. They now have a “buy” rating on the stock.
- 7/18/2024 – Revolution Medicines had its price target raised by analysts at Barclays PLC from $52.00 to $54.00. They now have an “overweight” rating on the stock.
- 7/16/2024 – Revolution Medicines had its price target raised by analysts at Oppenheimer Holdings Inc. from $45.00 to $55.00. They now have an “outperform” rating on the stock.
- 7/16/2024 – Revolution Medicines had its price target raised by analysts at Bank of America Co. from $48.00 to $55.00. They now have a “buy” rating on the stock.
- 7/16/2024 – Revolution Medicines had its price target raised by analysts at Needham & Company LLC from $46.00 to $62.00. They now have a “buy” rating on the stock.
- 7/16/2024 – Revolution Medicines had its price target raised by analysts at HC Wainwright from $44.00 to $56.00. They now have a “buy” rating on the stock.
- 7/12/2024 – Revolution Medicines is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $52.00 price target on the stock.
- 7/8/2024 – Revolution Medicines is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating and a $63.00 price target on the stock.
Revolution Medicines Stock Down 1.1 %
Shares of RVMD opened at $43.59 on Wednesday. Revolution Medicines, Inc. has a 12-month low of $15.44 and a 12-month high of $48.61. The business has a 50-day simple moving average of $42.56 and a two-hundred day simple moving average of $37.46. The stock has a market cap of $7.19 billion, a PE ratio of -11.62 and a beta of 1.44.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The business had revenue of $1.00 million during the quarter, compared to analyst estimates of $0.81 million. During the same period in the previous year, the firm posted ($0.92) earnings per share. The firm’s quarterly revenue was down 73.8% on a year-over-year basis. On average, equities research analysts expect that Revolution Medicines, Inc. will post -3.47 EPS for the current year.
Insider Buying and Selling at Revolution Medicines
Institutional Investors Weigh In On Revolution Medicines
Several institutional investors and hedge funds have recently made changes to their positions in RVMD. Bellevue Group AG boosted its holdings in Revolution Medicines by 7.8% in the fourth quarter. Bellevue Group AG now owns 5,091,000 shares of the company’s stock worth $146,010,000 after acquiring an additional 369,500 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Revolution Medicines in the first quarter worth approximately $6,656,000. Mass General Brigham Inc bought a new position in Revolution Medicines in the first quarter worth approximately $10,900,000. Finepoint Capital LP boosted its holdings in Revolution Medicines by 44.5% in the fourth quarter. Finepoint Capital LP now owns 617,100 shares of the company’s stock worth $17,698,000 after acquiring an additional 190,100 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Revolution Medicines by 0.8% in the first quarter. Vanguard Group Inc. now owns 14,757,112 shares of the company’s stock worth $475,622,000 after acquiring an additional 122,721 shares in the last quarter. Institutional investors own 94.34% of the company’s stock.
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Read More
- Five stocks we like better than Revolution Medicines
- Stock Average Calculator
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
- Consumer Discretionary Stocks Explained
- Brinker International Offers a Pullback Opportunity on EPS Miss
- What is a Bond Market Holiday? How to Invest and Trade
- Globant Is an Emerging AI Play That’s Expanding Its Footprint
Receive News & Ratings for Revolution Medicines Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines Inc and related companies with MarketBeat.com's FREE daily email newsletter.